The current $195 million investment is part of a commitment to invest more than $10 billion for innovation and manufacturing capacity enhancement.

Steve Grzanich has the business news of the day with the Wintrust Business Minute. Abbott Laboratories spinoff AbbVie will ...

The company’s commitment to its North Chicago, Ill. plant is part of a previously announced $10 billion capital investment ...

AbbVie (ABBV) announced a $195 million investment in its North Chicago manufacturing facility to boost domestic API production, reflecting its long-term commitment to U.S. manufacturing. Over the last ...

AbbVie will invest $195M to expand API manufacturing at its North Chicago plant, boosting U.S. pharmaceutical innovation, ...

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

The new North Chicago facility, slated to open in 2027, will boost domestic production of key drug ingredients for immunology ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a study titled ‘A Randomized ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

Drugmaker AbbVie plans to construct a $195 million facility near its headquarters in North Chicago to manufacture active pharmaceutical ingredients, The Chicago Tribune reported Aug. 12. Construction ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

AbbVie (NYSE: ABBV) has unveiled a $195 million investment to expand its North Chicago manufacturing plant to include domestic active pharmaceutical ingredient (API) production. The expansion is part ...